한글목차

세계의 호흡 케어 디바이스 시장 규모는 예측 기간 중 7.3%의 CAGR로 확대하며, 2025년 236억 달러에서 2030년에는 336억 달러에 달할 것으로 예측됩니다.

다양한 인구통계학적, 의학적, 환경적 결정 요인들이 호흡기 케어 기기 시장 성장을 가속하는 패키지를 형성하고 있습니다. 그 중 하나는 전 세계에서 호흡기 질환의 발생률 증가입니다. 천식, 수면무호흡증, 만성폐쇄성폐질환(COPD)과 같은 호흡기 질환은 호흡기 질환의 대표적인 예이며, 주요 원인은 흡연, 노화, 대기오염 수준 증가 등이며, COVID-19 기간 중 인공호흡기, 산소요법, 모니터링 장비에 대한 지출이 크게 증가하여 호흡기 지원에 대한 인식이 높아졌습니다. 에 대한 인식이 높아지고 있습니다.

치료 장비는 COPD, 천식, 수면 무호흡증, 호흡 부전 환자에게 생명 유지를 위한 호흡 요법을 제공하기 위해 COPD, 천식, 수면 무호흡증, 호흡 부전 환자에게 생명 유지를 위한 호흡 요법을 제공하기 위해 채택된 대부분의 급성 및 만성 호흡기 질환의 치료 및 관리에 필수적입니다. 이러한 장비에는 고유량 비강 캐뉼라 시스템, CPAP 및 BiPAP 장비, 분무기, 인공호흡기, 산소발생기 등이 포함됩니다. 치료 장비 시장은 장기적인 재택 호흡 치료의 필요성, 만성질환의 세계적 부담, 입원 등으로 인해 몇 배로 확대되고 있습니다.

만성폐쇄성폐질환(COPD)은 전 세계에서 만성폐쇄성폐질환(COPD), 특히 노인 인구의 질병으로 증가하고 있는 추세입니다. COPD는 진행성, 비가역성 질환으로 지속적인 관심과 장기적인 호흡기 치료가 필요하므로 비침습적 인공호흡기, 산소발생기, 분무기, 모니터에 대한 수요가 증가하고 있습니다. 또한 이 질환은 흡연, 대기오염, 직업적 노출 등 개발도상국 및 선진국 사회에 만연한 고위험 요인에 의해 발생하며, COPD는 입원 및 악화를 동반하므로 가정과 병원에서 호흡기 장비를 반복적으로 사용해야 합니다.

북미에서는 천식, 수면무호흡증, COPD와 같은 만성 호흡기 질환의 유병률이 증가하고 있으며, 그 배경에는 고령화, 오랜 흡연력, 비만율 증가가 있습니다. 이 지역에는 탄탄한 의료 시스템이 있고 호흡기 건강의 중요성에 대한 인식이 높아져 이러한 질병을 조기에 발견하고 치료할 수 있으며, COVID-19 팬데믹으로 인해 인공호흡기 및 산소 치료 장비에 대한 수요가 증가했습니다. 의료기기 제조업체는 상환 정책을 개선했습니다. 원격의료 및 원격 모니터링을 통합한 호흡기 장비와 같은 혁신 기술의 빠른 도입이 이 시장 형성에 일조하고 있습니다.

세계의 호흡 케어 디바이스 시장에 대해 조사했으며, 제품별, 적응 질환별, 최종사용자별, 지역별 동향 및 시장에 참여하는 기업의 개요 등을 정리하여 전해드립니다.

목차

제1장 서론

제2장 조사 방법

제3장 개요

제4장 주요 인사이트

제5장 시장 개요

• 서론
• 시장 역학
• 규제 상황
• 규제 구조
• 기술 분석
• 업계 동향
• 밸류체인 분석
• 공급망 분석
• 무역 분석
• 가격 분석
• 상환 시나리오
• Porter's Five Forces 분석
• 인접 시장 분석
• 특허 분석
• 에코시스템 커버 범위
• 주요 컨퍼런스와 이벤트(2025-2026년)
• 2025-2026년의 주요 컨퍼런스와 이벤트
• 사례 연구
• 고객 비즈니스에 영향을 미치는 동향/혼란
• 주요 이해관계자와 구입 기준
• 주요 구입 기준
• 투자/벤처캐피털
• 호흡 케어 디바이스 시장에서의 미충족 요구/최종사용자 기대
• 인공지능(AI)이 호흡 케어 디바이스 시장에 미치는 영향
• 2025년 미국 관세의 영향 - 개요
• 주요 관세율
• 가격 영향 분석
• 최종사용자 산업에 대한 영향

제6장 호흡 케어 디바이스 시장(제품별)

• 서론
• 치료용 호흡 케어 디바이스
• 모니터링 디바이스
• 진단용 호흡 케어 디바이스
• 소모품, 액세서리

제7장 호흡 케어 디바이스 시장(적응 질환별)

• 서론
• 만성폐쇄성폐질환(COPD)
• 수면무호흡
• 천식
• 감염증
• 기타

제8장 호흡 케어 디바이스 시장(최종사용자별)

• 서론
• 병원
• 홈케어
• 외래 케어 센터(ACCS)
• 기타

제9장 호흡 케어 디바이스 시장(지역별)

• 서론
• 북미
  • 북미의 거시경제 전망
  • 미국
  • 캐나다
• 유럽
  • 유럽의 거시경제 전망
  • 독일
  • 프랑스
  • 영국
  • 이탈리아
  • 스페인
  • 기타
• 아시아태평양
  • 아시아태평양의 거시경제 전망
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 기타
• 라틴아메리카
  • 라틴아메리카의 거시경제 전망
  • 브라질
  • 멕시코
  • 기타
• 중동 및 아프리카
  • 중동 및 아프리카의 거시경제 전망
  • GCC 국가
  • 기타

제10장 경쟁 구도

• 개요
• 주요 참여 기업의 전략/강점
• 매출 분석
• 시장 점유율 분석
• 기업 평가 매트릭스 : 주요 참여 기업, 2024년
• 기업 평가 매트릭스 : 스타트업/중소기업, 2023년
• 평가와 재무 지표
• 브랜드/제품 비교
• 경쟁 시나리오

제11장 기업 개요

• 주요 참여 기업
  • KONINKLIJKE PHILIPS N.V.
  • MEDTRONIC
  • RESMED INC.
  • FISHER & PAYKEL HEALTHCARE LIMITED
  • DRAGERWERK AG & CO. KGAA
  • MASIMO
  • GETINGE
  • NIHON KOHDEN CORPORATION
  • GE HEALTHCARE
  • HILLROM & WELCH ALLYN(BAXTER INTERNATIONAL, INC)
  • ADAPTHEALTH, LLC
  • TELEFLEX INCORPORATED
  • AIR LIQUIDE
  • ICU MEDICAL, INC.
  • HAMILTON MEDICAL
• 기타 기업
  • MEDLINE INDUSTRIES, LP
  • ALLIED MEDICAL LLC
  • NONIN
  • APEX MEDICAL
  • ROTECH HEALTHCARE, INC.
  • LOWENSTEIN MEDICAL SE & CO. KG
  • WEINMANN EMERGENCY MEDICAL TECHNOLOGY GMBH+CO. KG
  • DRIVE DEVILBISS HEALTHCARE
  • OMRON HEALTHCARE, INC.
  • HUM GMBH

제12장 부록

영문목차

The global respiratory care devices market is projected to reach USD 33.6 billion by 2030 from USD 23.6 billion in 2025, at a CAGR of 7.3% during the forecast period.

Various demographic, medical, and environmental determinants form a package fueling market growth in respiratory care equipment. One of them is the increase in the global incidence of respiratory disease. Respiratory diseases such as asthma, sleep apnea, and chronic obstructive pulmonary disease (COPD) are typical examples of respiratory disease, largely because of smoking, aging, and increasingly increasing levels of air pollution. Respiratory support awareness increased with mass deployment of spending on ventilators, oxygen therapy, and monitoring devices during the COVID-19 period.

By product type, the therapeutic devices segment is expected to have the largest market share in the respiratory care devices market.

Therapeutic devices are essential in the treatment and management of most acute and chronic respiratory diseases. They are employed to provide life-supporting respiratory therapy to COPD, asthma, sleep apnea, and respiratory failure patients. The devices include high-flow nasal cannula systems, CPAP and BiPAP devices, nebulizers, ventilators, and oxygen concentrators. The therapeutic equipment market has expanded multi-fold due to the need for long-term home respiratory therapy, the global burden of chronic disease, and hospitalization.

By disease indication, the COPD segment is expected to have the largest market share in the respiratory care devices market.

The respiratory care equipment is dominated by Chronic Obstructive Pulmonary Disease (COPD), which is increasingly a global disease, especially in the geriatric population. This is because of the higher demand for non-invasive ventilators, oxygen concentrators, nebulizers, and monitors. Since COPD is a progressive and irreversible disease, constant attention and long-term respiratory treatment are required for the same. The disease is also caused by high-risk factors prevalent in developing and industrialized societies, including smoking, air pollution, and occupational exposures. Since COPD is hospitalized and has exacerbations, repeated use of respiratory equipment in the home and hospital setting is necessitated.

North America is expected to have the largest market share in the respiratory care devices market.

In North America, the increasing prevalence of chronic respiratory conditions such as asthma, sleep apnea, and COPD can be attributed to an aging population, a long history of smoking, and the growing rates of obesity. The region has a robust healthcare system and a growing awareness of the importance of respiratory health, which allows for early detection and treatment of these conditions. The COVID-19 pandemic boosted the demand for ventilators and oxygen therapy equipment. Medical device manufacturers improved reimbursement policies. There has been a rapid adoption of innovative technologies such as respiratory devices that integrate telehealth and remote monitoring have all played a role in shaping this market.

A breakdown of the primary participants (supply-side) for the respiratory care devices market referred to in this report is provided below:

• By Company Type: Tier 1: 35%, Tier 2: 40%, and Tier 3: 25%
• By Designation: C-level: 45%, Director Level: 35%, and Others: 20%
• By Region: North America: 27%, Europe: 25%, Asia Pacific: 30%, Latin America: 8%, Middle East & Africa: 10%

Prominent players in the respiratory care devices market are Koninklijke Philips N.V. (Netherlands), Medtronic (Ireland), ResMed Inc. (US), Fisher & Paykel Healthcare Limited (New Zealand), and Dragerwerk AG & Co. KGaA (Germany).

Research Coverage

The report analyzes the respiratory care devices market and aims to estimate the market size and future growth potential of this market based on various segments such as product type, application, end user, and region. The report also includes a competitive analysis of the key players in this market, along with their company profiles, service offerings, recent developments, and key market strategies.

Reasons to Buy the Report

The report will help the market leaders/new entrants by providing information on the closest approximations of the revenue numbers for the overall respiratory care devices market. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.

This report provides insights into the following pointers:

• Analysis of key drivers (increasing prevalence of respiratory diseases, surge in preterm births, Growing outbreaks of infectious diseases affecting respiratory system, rising issue of sleep disorders, increasing focus on improved patient outcomes, rising R&D investments for medical devices), restraints (unfavorable reimbursement scenario, availability of low-cost products from local manufacturers, high cost of continuous positive airway pressure machines), opportunities (growing demand for home care therapeutic devices, Opportunities in emerging markets, increasing preference for self-testing, growing awareness about ill effects of untreated sleep apnea) and challenges (low awareness and lack of diagnosis of respiratory diseases, harmful effects of respiratory care devices on neonates, lack of patient compliance with CPAP therapy)
• Market Penetration: It includes extensive information on products offered by the major players in the global respiratory care devices market. The report includes various segments in product type, disease indication, end user, and region.
• Product Enhancement/Innovation: Comprehensive details about product launches and anticipated trends in the global respiratory care devices market
• Market Development: Thorough knowledge and analysis of the profitable rising markets by type, disease indication, end user, and region.
• Market Diversification: Comprehensive information about newly launched products, expanding markets, current advancements, and investments in the global respiratory care devices market
• Competitive Assessment: Thorough evaluation of the market shares, growth plans, offerings of products, and capacities of the major competitors in the global respiratory care devices market.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
  • 1.2.1 INCLUSIONS AND EXCLUSIONS
• 1.3 MARKET SCOPE
  • 1.3.1 MARKETS COVERED
  • 1.3.2 YEARS CONSIDERED
• 1.4 CURRENCY CONSIDERED
• 1.5 STAKEHOLDERS
• 1.6 LIMITATIONS
• 1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
    • 2.1.1.1 Key data from secondary sources
  • 2.1.2 PRIMARY DATA
    • 2.1.2.1 Key data from primary sources
    • 2.1.2.2 Key industry insights
• 2.2 MARKET SIZE ESTIMATION
• 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
• 2.4 ASSUMPTIONS
  • 2.4.1 MARKET SHARE ASSUMPTIONS
  • 2.4.2 RESEARCH ASSUMPTIONS
• 2.5 RISK ASSESSMENT
• 2.6 METHODOLOGY-RELATED LIMITATIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 RESPIRATORY CARE DEVICES MARKET OVERVIEW
• 4.2 ASIA PACIFIC: RESPIRATORY CARE DEVICES MARKET, 2024
• 4.3 RESPIRATORY CARE DEVICES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
• 4.4 RESPIRATORY CARE DEVICES MARKET: GEOGRAPHIC MIX
• 4.5 RESPIRATORY CARE DEVICES MARKET: DEVELOPING VS. DEVELOPED MARKETS

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Rising prevalence of respiratory diseases
      • 5.2.1.1.1 Rapid growth in global geriatric population
      • 5.2.1.1.2 Urbanization and growing pollution levels
      • 5.2.1.1.3 Growing tobacco consumption
      • 5.2.1.1.4 Increased adoption of sedentary lifestyles
    • 5.2.1.2 Surging incidence rate of preterm births
    • 5.2.1.3 Growing outbreaks of infectious diseases affecting respiratory systems
    • 5.2.1.4 Rising population with sleep disorders
    • 5.2.1.5 Improved patient outcomes using respiratory care devices
    • 5.2.1.6 Rising R&D investments for technological advancement of medical devices
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 Unfavorable reimbursement scenario for respiratory care diagnostics
    • 5.2.2.2 Availability of low-cost products from local manufacturers
    • 5.2.2.3 High cost of CPAP machines
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Growing demand for home care therapeutic devices
    • 5.2.3.2 Market growth opportunities in Asia Pacific
    • 5.2.3.3 Increasing preference for self-testing
    • 5.2.3.4 Growing awareness about ill effects of untreated sleep apnea
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Low awareness and lack of diagnosis of respiratory diseases
    • 5.2.4.2 Harmful effects of certain respiratory care devices on neonates
    • 5.2.4.3 Lack of patient compliance with CPAP therapy
• 5.3 REGULATORY LANDSCAPE
• 5.4 REGULATORY FRAMEWORK
  • 5.4.1 NORTH AMERICA
    • 5.4.1.1 US
    • 5.4.1.2 Canada
  • 5.4.2 EUROPE
  • 5.4.3 ASIA PACIFIC
    • 5.4.3.1 Japan
    • 5.4.3.2 China
    • 5.4.3.3 India
  • 5.4.4 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• 5.5 TECHNOLOGY ANALYSIS
  • 5.5.1 KEY TECHNOLOGIES
    • 5.5.1.1 OXYGEN THERAPY SYSTEMS
    • 5.5.1.2 AIRWAY MANAGEMENT DEVICES
    • 5.5.1.3 PULMONARY FUNCTION TESTING (PFT) DEVICES
    • 5.5.1.4 MONITORING SENSORS
  • 5.5.2 COMPLEMENTARY TECHNOLOGIES
    • 5.5.2.1 TELEMEDICINE PLATFORMS
    • 5.5.2.2 MOBILE HEALTH (MHEALTH) APPS
    • 5.5.2.3 WEARABLE RESPIRATORY TRACKERS
  • 5.5.3 ADJACENT TECHNOLOGIES
    • 5.5.3.1 SMART INHALERS
    • 5.5.3.2 ENVIRONMENTAL SENSING DEVICES
• 5.6 INDUSTRY TRENDS
  • 5.6.1 MINIATURIZATION AND PORTABILITY
  • 5.6.2 SMART CONNECTIVITY AND IOT (INTERNET OF THINGS) INTEGRATION
  • 5.6.3 GROWING DEMAND FOR MULTIMODAL VENTILATION
  • 5.6.4 RISING ADOPTION OF NON-INVASIVE VENTILATION
  • 5.6.5 PERSONALIZED TREATMENT SOLUTIONS
• 5.7 VALUE CHAIN ANALYSIS
• 5.8 SUPPLY CHAIN ANALYSIS
• 5.9 TRADE ANALYSIS
  • 5.9.1 TRADE ANALYSIS FOR RESPIRATORY CARE DEVICES PRODUCTS
• 5.10 PRICING ANALYSIS
  • 5.10.1 AVERAGE SELLING PRICE OF RESPIRATORY CARE DEVICES, BY KEY PLAYER, 2024 (USD)
  • 5.10.2 AVERAGE SELLING PRICE OF RESPIRATORY CARE DEVICES, BY REGION, 2024 (USD)
• 5.11 REIMBURSEMENT SCENARIO
• 5.12 PORTER'S FIVE FORCES ANALYSIS
  • 5.12.1 THREAT OF NEW ENTRANTS
  • 5.12.2 THREAT OF SUBSTITUTES
  • 5.12.3 BARGAINING POWER OF SUPPLIERS
  • 5.12.4 BARGAINING POWER OF BUYERS
  • 5.12.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.13 ADJACENT MARKET ANALYSIS
• 5.14 PATENT ANALYSIS
• 5.15 ECOSYSTEM COVERAGE
• 5.16 KEY CONFERENCES AND EVENTS (2025-2026)
• 5.17 KEY CONFERENCES & EVENTS DURING 2025-2026
• 5.18 CASE STUDIES
• 5.19 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.20 KEY STAKEHOLDERS & BUYING CRITERIA
  • 5.20.1 KEY STAKEHOLDERS IN BUYING PROCESS
• 5.21 KEY BUYING CRITERIA
• 5.22 INVESTMENT/VENTURE CAPITAL
• 5.23 UNMET NEEDS/END-USER EXPECTATIONS IN RESPIRATORY CARE DEVICES MARKET
• 5.24 IMPACT OF ARTIFICIAL INTELLIGENCE (AI) ON RESPIRATORY CARE DEVICES MARKET
• 5.25 IMPACT OF 2025 US TARIFF - OVERVIEW
  • 5.25.1 INTRODUCTION
• 5.26 KEY TARIFF RATES
• 5.27 PRICE IMPACT ANALYSIS
  • 5.27.1 IMPACT ON COUNTRY/REGION
    • 5.27.1.1 US
    • 5.27.1.2 Europe
    • 5.27.1.3 Asia Pacific
• 5.28 IMPACT ON END-USER INDUSTRIES

6 RESPIRATORY CARE DEVICES MARKET, BY PRODUCT

• 6.1 INTRODUCTION
• 6.2 THERAPEUTIC RESPIRATORY CARE DEVICES
  • 6.2.1 PAP DEVICES
    • 6.2.1.1 CPAP devices
      • 6.2.1.1.1 Growing popularity of nasal CPAP therapies to drive demand
    • 6.2.1.2 APAP devices
      • 6.2.1.2.1 Rising awareness among sleep specialists and patients regarding additional features of APAP devices to boost market
    • 6.2.1.3 BiPAP devices
      • 6.2.1.3.1 Increasing number of hospitals to strengthen market
  • 6.2.2 VENTILATORS
    • 6.2.2.1 ICU ventilators
      • 6.2.2.1.1 High-end ventilators
        • 6.2.2.1.1.1 Improving healthcare infrastructure and rising healthcare expenditure to drive market
      • 6.2.2.1.2 Mid-end ventilators
        • 6.2.2.1.2.1 Better affordability and accessibility of mid-end ventilators than high-end models to support market growth
      • 6.2.2.1.3 Basic ventilators
        • 6.2.2.1.3.1 Expanding access to critical healthcare facilities in developing countries to spur demand
    • 6.2.2.2 Portable/Transportable ventilators
      • 6.2.2.2.1 Increasing demand for home care to boost segmental growth
  • 6.2.3 NEBULIZERS
    • 6.2.3.1 Jet nebulizers
      • 6.2.3.1.1 Increasing prevalence of respiratory conditions to augment market
    • 6.2.3.2 Mesh nebulizers
      • 6.2.3.2.1 Deployment of advanced aerosolization technology to drive market
    • 6.2.3.3 Ultrasonic nebulizers
      • 6.2.3.3.1 Adjustable settings for particle size and treatment duration to boost market
  • 6.2.4 HUMIDIFIERS
    • 6.2.4.1 Heated humidifiers
      • 6.2.4.1.1 Ease of control and customizability to fuel market
    • 6.2.4.2 Passover humidifiers
      • 6.2.4.2.1 Minimal maintenance and simple technology to spur demand
  • 6.2.5 OXYGEN CONCENTRATORS
    • 6.2.5.1 Fixed oxygen concentrators
      • 6.2.5.1.1 Better access to healthcare services to spur demand
    • 6.2.5.2 Portable oxygen concentrators
      • 6.2.5.2.1 Low weight and easy setup to drive segmental growth
  • 6.2.6 INHALERS
    • 6.2.6.1 Metered-dose inhalers (MDIs)
      • 6.2.6.1.1 Ongoing advancements in MDI technology to support market growth
    • 6.2.6.2 Dry powder inhalers (DPIs)
      • 6.2.6.2.1 Developments in particle engineering and powder formulations to boost segmental growth
  • 6.2.7 REUSABLE RESUSCITATORS
    • 6.2.7.1 Disposable and reusable nature to drive demand
  • 6.2.8 NITRIC OXIDE DELIVERY UNITS
    • 6.2.8.1 Rising emphasis of companies on developing innovative and advanced nitric oxide delivery units to drive market
  • 6.2.9 OXYGEN HOODS
    • 6.2.9.1 Growing prevalence of respiratory diseases in kids to drive market growth
• 6.3 MONITORING DEVICES
  • 6.3.1 PULSE OXIMETERS
    • 6.3.1.1 Pulse oximeter sensors
      • 6.3.1.1.1 Development of advanced sensors with embedded chips to boost segmental growth
    • 6.3.1.2 Pulse oximeter equipment
      • 6.3.1.2.1 Growing prevalence of chronic respiratory conditions to boost demand
  • 6.3.2 CAPNOGRAPHS
    • 6.3.2.1 Ongoing R&D on capnographs to offer lucrative growth opportunities
  • 6.3.3 GAS ANALYZERS
    • 6.3.3.1 Increasing demand for point-of-care testing to drive demand
• 6.4 DIAGNOSTIC RESPIRATORY CARE DEVICES
  • 6.4.1 SPIROMETERS
    • 6.4.1.1 Rising technological advancements in spirometers to support market growth
  • 6.4.2 POLYSOMNOGRAPHY DEVICES (PSG DEVICES)
    • 6.4.2.1 Rising incidence of obstructive sleep apnea to drive demand
  • 6.4.3 PEAK FLOW METERS
    • 6.4.3.1 Low-cost and uncomplicated nature to drive segmental growth
  • 6.4.4 OTHER DIAGNOSTIC DEVICES
• 6.5 CONSUMABLES & ACCESSORIES
  • 6.5.1 MASKS
    • 6.5.1.1 Reusable masks
      • 6.5.1.1.1 Growing concerns related to air pollution to fuel demand
    • 6.5.1.2 Disposable masks
      • 6.5.1.2.1 Stringent government mandates on wearing masks to spur demand
  • 6.5.2 DISPOSABLE RESUSCITATORS
    • 6.5.2.1 Growing focus on reducing cross-contamination cases in patients to foster segmental growth
  • 6.5.3 TRACHEOSTOMY TUBES
    • 6.5.3.1 Introduction of advanced products with ergonomic designs to drive market growth
  • 6.5.4 BREATHING CIRCUITS
    • 6.5.4.1 Healthcare professionals' efforts to improve infection control practices to drive demand
  • 6.5.5 NASAL CANNULAE
    • 6.5.5.1 Increasing focus on minimally invasive surgery techniques to fuel demand
  • 6.5.6 OTHER CONSUMABLES & ACCESSORIES

7 RESPIRATORY CARE DEVICES MARKET, BY DISEASE INDICATION

• 7.1 INTRODUCTION
• 7.2 CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
  • 7.2.1 RISING INDOOR AND OUTDOOR AIR POLLUTION LEVELS TO DRIVE MARKET
• 7.3 SLEEP APNEA
  • 7.3.1 GROWING INCIDENCE OF OBESITY AND CARDIOVASCULAR DISEASES TO FAVOR MARKET GROWTH
• 7.4 ASTHMA
  • 7.4.1 INCREASING AIR POLLUTION AND GROWING USE OF TOBACCO-BASED PRODUCTS TO DRIVE MARKET
• 7.5 INFECTIOUS DISEASES
  • 7.5.1 GROWING NUMBER OF TB PATIENTS TO BOOST MARKET GROWTH
• 7.6 OTHER DISEASE INDICATIONS

8 RESPIRATORY CARE DEVICES MARKET, BY END USER

• 8.1 INTRODUCTION
• 8.2 HOSPITALS
  • 8.2.1 GROWING NUMBER OF HOSPITALS IN EMERGING ECONOMIES TO DRIVE MARKET
• 8.3 HOME CARE SETTINGS
  • 8.3.1 INCREASING ACCEPTANCE OF HOME CARE DEVICES BY PATIENTS TO BOOST GROWTH
• 8.4 AMBULATORY CARE CENTERS (ACCS)
  • 8.4.1 IMPROVED PATIENT EXPERIENCE IN AMBULATORY CARE CENTERS TO DRIVE MARKET
• 8.5 OTHER END USERS

9 RESPIRATORY CARE DEVICES MARKET, BY REGION

• 9.1 INTRODUCTION
• 9.2 NORTH AMERICA
  • 9.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 9.2.2 US
    • 9.2.2.1 Rapid growth in geriatric population to boost market
  • 9.2.3 CANADA
    • 9.2.3.1 Large pool of undiagnosed patients and vaping trends drive market
• 9.3 EUROPE
  • 9.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 9.3.2 GERMANY
    • 9.3.2.1 Increasing public healthcare expenditure to foster market growth
  • 9.3.3 FRANCE
    • 9.3.3.1 High prevalence of COPD to surge demand
  • 9.3.4 UK
    • 9.3.4.1 Growing demand for minimally invasive surgeries to drive market
  • 9.3.5 ITALY
    • 9.3.5.1 Growing involvement of private sector in healthcare market to drive market
  • 9.3.6 SPAIN
    • 9.3.6.1 Need to improve healthcare infrastructure due to aging demographic to drive demand
  • 9.3.7 REST OF EUROPE
• 9.4 ASIA PACIFIC
  • 9.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 9.4.2 JAPAN
    • 9.4.2.1 Availability of universal healthcare reimbursement policy to drive market
  • 9.4.3 CHINA
    • 9.4.3.1 Initiatives to modernize healthcare system and reimbursement facilities to support market growth
  • 9.4.4 INDIA
    • 9.4.4.1 Increasing focus of global players on domestic market to drive market
  • 9.4.5 AUSTRALIA
    • 9.4.5.1 High prevalence of chronic lung diseases to drive demand
  • 9.4.6 SOUTH KOREA
    • 9.4.6.1 Expanding geriatric population to fuel market
  • 9.4.7 REST OF ASIA PACIFIC
• 9.5 LATIN AMERICA
  • 9.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 9.5.2 BRAZIL
    • 9.5.2.1 Government initiatives to improve healthcare sector to drive market
  • 9.5.3 MEXICO
    • 9.5.3.1 Rising obesity rate to increase incidence of respiratory diseases
  • 9.5.4 REST OF LATIN AMERICA
• 9.6 MIDDLE EAST & AFRICA
  • 9.6.1 MACROECONOMIC OUTLOOK FOR MEA
  • 9.6.2 GCC COUNTRIES
    • 9.6.2.1 INCREASING INCIDENCE OF RESPIRATORY DISEASES IN GCC DRIVES MARKET
  • 9.6.3 REST OF MIDDLE EAST & AFRICA

10 COMPETITIVE LANDSCAPE

• 10.1 OVERVIEW
• 10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • 10.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN RESPIRATORY CARE DEVICES MARKET
• 10.3 REVENUE ANALYSIS
• 10.4 MARKET SHARE ANALYSIS
• 10.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
  • 10.5.1 STARS
  • 10.5.2 EMERGING LEADERS
  • 10.5.3 PERVASIVE PLAYERS
  • 10.5.4 PARTICIPANTS
  • 10.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
    • 10.5.5.1 Company footprint
    • 10.5.5.2 Region footprint
    • 10.5.5.3 Product type footprint
    • 10.5.5.4 Disease indication footprint
    • 10.5.5.5 End user footprint
• 10.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
  • 10.6.1 PROGRESSIVE COMPANIES
  • 10.6.2 DYNAMIC COMPANIES
  • 10.6.3 STARTING BLOCKS
  • 10.6.4 RESPONSIVE COMPANIES
  • 10.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
• 10.7 VALUATION & FINANCIAL METRICS
  • 10.7.1 FINANCIAL METRICS
  • 10.7.2 COMPANY VALUATION
• 10.8 BRAND/PRODUCT COMPARISON
• 10.9 COMPETITIVE SCENARIO
  • 10.9.1 PRODUCT & SERVICE LAUNCHES AND APPROVALS
  • 10.9.2 DEALS
  • 10.9.3 EXPANSIONS
  • 10.9.4 OTHER DEVELOPMENTS

11 COMPANY PROFILES

• 11.1 KEY PLAYERS
  • 11.1.1 KONINKLIJKE PHILIPS N.V.
    • 11.1.1.1 Business overview
    • 11.1.1.2 Products offered
    • 11.1.1.3 Recent developments
      • 11.1.1.3.1 Product launches & approvals
    • 11.1.1.4 MnM view
      • 11.1.1.4.1 Right to win
      • 11.1.1.4.2 Strategic choices
      • 11.1.1.4.3 Weaknesses & competitive threats
  • 11.1.2 MEDTRONIC
    • 11.1.2.1 Business overview
    • 11.1.2.2 Products offered
    • 11.1.2.3 Recent developments
      • 11.1.2.3.1 Product launches & approvals
      • 11.1.2.3.2 Other developments
    • 11.1.2.4 MnM view
      • 11.1.2.4.1 Right to win
      • 11.1.2.4.2 Strategic choices
      • 11.1.2.4.3 Weaknesses & competitive threats
  • 11.1.3 RESMED INC.
    • 11.1.3.1 Business overview
    • 11.1.3.2 Products offered
    • 11.1.3.3 Recent developments
      • 11.1.3.3.1 Product launches & approvals
      • 11.1.3.3.2 Deals
    • 11.1.3.4 MnM view
      • 11.1.3.4.1 Right to win
      • 11.1.3.4.2 Strategic choices
      • 11.1.3.4.3 Weaknesses & competitive threats
  • 11.1.4 FISHER & PAYKEL HEALTHCARE LIMITED
    • 11.1.4.1 Business overview
    • 11.1.4.2 Products offered
    • 11.1.4.3 Recent developments
      • 11.1.4.3.1 Product launches & approvals
    • 11.1.4.4 MnM view
      • 11.1.4.4.1 Right to win
      • 11.1.4.4.2 Strategic choices
      • 11.1.4.4.3 Weaknesses & competitive threats
  • 11.1.5 DRAGERWERK AG & CO. KGAA
    • 11.1.5.1 Business overview
    • 11.1.5.2 Products offered
    • 11.1.5.3 Recent developments
      • 11.1.5.3.1 Product launches & approvals
      • 11.1.5.3.2 Deals
      • 11.1.5.3.3 Other developments
    • 11.1.5.4 MnM view
      • 11.1.5.4.1 Right to win
      • 11.1.5.4.2 Strategic choices
      • 11.1.5.4.3 Weaknesses & competitive threats
  • 11.1.6 MASIMO
    • 11.1.6.1 Business overview
    • 11.1.6.2 Products offered
    • 11.1.6.3 Recent developments
      • 11.1.6.3.1 Product launches & approvals
      • 11.1.6.3.2 Deals
      • 11.1.6.3.3 Other developments
  • 11.1.7 GETINGE
    • 11.1.7.1 Business overview
    • 11.1.7.2 Products offered
    • 11.1.7.3 Recent developments
      • 11.1.7.3.1 Product launches & approvals
      • 11.1.7.3.2 Deals
      • 11.1.7.3.3 Expansions
  • 11.1.8 NIHON KOHDEN CORPORATION
    • 11.1.8.1 Business overview
    • 11.1.8.2 Products offered
    • 11.1.8.3 Recent developments
      • 11.1.8.3.1 Product launches & approvals
      • 11.1.8.3.2 Deals
  • 11.1.9 GE HEALTHCARE
    • 11.1.9.1 Business overview
    • 11.1.9.2 Products offered
    • 11.1.9.3 Recent developments
      • 11.1.9.3.1 Deals
      • 11.1.9.3.2 Other developments
  • 11.1.10 HILLROM & WELCH ALLYN (BAXTER INTERNATIONAL, INC)
    • 11.1.10.1 Business overview
    • 11.1.10.2 Products offered
    • 11.1.10.3 Recent developments
      • 11.1.10.3.1 Product launches & approvals
      • 11.1.10.3.2 Deals
  • 11.1.11 ADAPTHEALTH, LLC
    • 11.1.11.1 Business overview
    • 11.1.11.2 Products offered
  • 11.1.12 TELEFLEX INCORPORATED
    • 11.1.12.1 Business overview
    • 11.1.12.2 Products offered
  • 11.1.13 AIR LIQUIDE
    • 11.1.13.1 Business overview
    • 11.1.13.2 Products offered
    • 11.1.13.3 Recent developments
      • 11.1.13.3.1 Deals
  • 11.1.14 ICU MEDICAL, INC.
    • 11.1.14.1 Business overview
    • 11.1.14.2 Products offered
    • 11.1.14.3 Recent developments
      • 11.1.14.3.1 Product launches & approvals
      • 11.1.14.3.2 Deals
  • 11.1.15 HAMILTON MEDICAL
    • 11.1.15.1 Business overview
    • 11.1.15.2 Products offered
    • 11.1.15.3 Recent developments
      • 11.1.15.3.1 Product launches & approvals
• 11.2 OTHER PLAYERS
  • 11.2.1 MEDLINE INDUSTRIES, LP
  • 11.2.2 ALLIED MEDICAL LLC
  • 11.2.3 NONIN
  • 11.2.4 APEX MEDICAL
  • 11.2.5 ROTECH HEALTHCARE, INC.
  • 11.2.6 LOWENSTEIN MEDICAL SE & CO. KG
  • 11.2.7 WEINMANN EMERGENCY MEDICAL TECHNOLOGY GMBH + CO. KG
  • 11.2.8 DRIVE DEVILBISS HEALTHCARE
  • 11.2.9 OMRON HEALTHCARE, INC.
  • 11.2.10 HUM GMBH

12 APPENDIX

• 12.1 DISCUSSION GUIDE
• 12.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 12.3 CUSTOMIZATION OPTIONS
• 12.4 RELATED REPORTS
• 12.5 AUTHOR DETAILS